Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies

Yevgeniy Balagula, Mario E. Lacouture, Jonathan A. Cotliar

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The discovery of the intricate intracellular signaling networks that regulate normal cellular proliferation and survival but can also drive the oncogenic process when aberrantly activated has led to the emergence of targeted agents in oncology. The introduction of such agents has resulted in improved survival and more tolerable treatments, reducing systemic toxicities such as myelosuppression. Nevertheless, it has become evident that these agents are associated with a wide spectrum of dermatologic toxicities that often manifest in cosmetically sensitive areas and may affect the majority of patients. Associated pain and pruritus can negatively impact quality of life, resulting in dose modification or treatment interruptions that interfere with potentially life-prolonging therapy. Extensive efforts throughout the past decade have concentrated on describing the clinicohistopathologic characteristics, elucidating the underlying mechanisms, and investigating potential management strategies. Currently, however, proposed treatment guidelines arise from expert opinions, anecdotal evidence, and few data from clinical trials. This article reviews the spectrum of dermatologic toxicities associated with a variety of targeted agents used alone or in combination with other modalities, delineating their clinical presentation, underlying mechanisms, and management options.

Original languageEnglish (US)
Pages (from-to)149-161
Number of pages13
JournalJournal of Supportive Oncology
Volume8
Issue number4
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Survival
Expert Testimony
Therapeutics
Pruritus
Quality of Life
Cell Proliferation
Clinical Trials
Guidelines
Pain
Drive

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies. / Balagula, Yevgeniy; Lacouture, Mario E.; Cotliar, Jonathan A.

In: Journal of Supportive Oncology, Vol. 8, No. 4, 07.2010, p. 149-161.

Research output: Contribution to journalArticle

Balagula, Yevgeniy ; Lacouture, Mario E. ; Cotliar, Jonathan A. / Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies. In: Journal of Supportive Oncology. 2010 ; Vol. 8, No. 4. pp. 149-161.
@article{0d655d7c0da245b39f33e67da9676d1a,
title = "Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies",
abstract = "The discovery of the intricate intracellular signaling networks that regulate normal cellular proliferation and survival but can also drive the oncogenic process when aberrantly activated has led to the emergence of targeted agents in oncology. The introduction of such agents has resulted in improved survival and more tolerable treatments, reducing systemic toxicities such as myelosuppression. Nevertheless, it has become evident that these agents are associated with a wide spectrum of dermatologic toxicities that often manifest in cosmetically sensitive areas and may affect the majority of patients. Associated pain and pruritus can negatively impact quality of life, resulting in dose modification or treatment interruptions that interfere with potentially life-prolonging therapy. Extensive efforts throughout the past decade have concentrated on describing the clinicohistopathologic characteristics, elucidating the underlying mechanisms, and investigating potential management strategies. Currently, however, proposed treatment guidelines arise from expert opinions, anecdotal evidence, and few data from clinical trials. This article reviews the spectrum of dermatologic toxicities associated with a variety of targeted agents used alone or in combination with other modalities, delineating their clinical presentation, underlying mechanisms, and management options.",
author = "Yevgeniy Balagula and Lacouture, {Mario E.} and Cotliar, {Jonathan A.}",
year = "2010",
month = "7",
language = "English (US)",
volume = "8",
pages = "149--161",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "4",

}

TY - JOUR

T1 - Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies

AU - Balagula, Yevgeniy

AU - Lacouture, Mario E.

AU - Cotliar, Jonathan A.

PY - 2010/7

Y1 - 2010/7

N2 - The discovery of the intricate intracellular signaling networks that regulate normal cellular proliferation and survival but can also drive the oncogenic process when aberrantly activated has led to the emergence of targeted agents in oncology. The introduction of such agents has resulted in improved survival and more tolerable treatments, reducing systemic toxicities such as myelosuppression. Nevertheless, it has become evident that these agents are associated with a wide spectrum of dermatologic toxicities that often manifest in cosmetically sensitive areas and may affect the majority of patients. Associated pain and pruritus can negatively impact quality of life, resulting in dose modification or treatment interruptions that interfere with potentially life-prolonging therapy. Extensive efforts throughout the past decade have concentrated on describing the clinicohistopathologic characteristics, elucidating the underlying mechanisms, and investigating potential management strategies. Currently, however, proposed treatment guidelines arise from expert opinions, anecdotal evidence, and few data from clinical trials. This article reviews the spectrum of dermatologic toxicities associated with a variety of targeted agents used alone or in combination with other modalities, delineating their clinical presentation, underlying mechanisms, and management options.

AB - The discovery of the intricate intracellular signaling networks that regulate normal cellular proliferation and survival but can also drive the oncogenic process when aberrantly activated has led to the emergence of targeted agents in oncology. The introduction of such agents has resulted in improved survival and more tolerable treatments, reducing systemic toxicities such as myelosuppression. Nevertheless, it has become evident that these agents are associated with a wide spectrum of dermatologic toxicities that often manifest in cosmetically sensitive areas and may affect the majority of patients. Associated pain and pruritus can negatively impact quality of life, resulting in dose modification or treatment interruptions that interfere with potentially life-prolonging therapy. Extensive efforts throughout the past decade have concentrated on describing the clinicohistopathologic characteristics, elucidating the underlying mechanisms, and investigating potential management strategies. Currently, however, proposed treatment guidelines arise from expert opinions, anecdotal evidence, and few data from clinical trials. This article reviews the spectrum of dermatologic toxicities associated with a variety of targeted agents used alone or in combination with other modalities, delineating their clinical presentation, underlying mechanisms, and management options.

UR - http://www.scopus.com/inward/record.url?scp=77956131018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956131018&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 149

EP - 161

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 4

ER -